The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 487 participants.

Also called NCT02352402

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 487 participants (planned count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as a collaborator
Registry
  • NCT NCT02352402
  • EudraCT 2014-002142-50
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02352402. Randomized; quadruple masking; primary purpose treatment. Start 2015-03 (registry gives no type); primary completion 2020-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery
Acronym
POPular CABG
Condition
Stable Angina
Condition
Acute Coronary Syndrome
Intervention (Drug)
Ticagrelor
Intervention (Drug)
Placebo
Lead sponsor
J.M. ten Berg (class: other)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02352402
Content hash
dc30db0147e4a76b67d89f71f1b2916fed53978c9bb7c5febcc14cc4f327c5dc